ACADIA Pharmaceuticals, Inc.

-$2.11 (-9.2%)
Closing price January 18, 2022
Canaccord Genuity recently released a report detailing some of the biggest biotech catalysts coming out over these next six months.
Thursday's top analyst upgrades and downgrades included Bed Bath & Beyond, Ciena, DocuSign, eHealth, Faceboook, Netflix, PNC Financial Services, Square, Tilray, Twitter and Zoom Video Communications.
Monday's top analyst upgrades, downgrades and initiations included Adobe, Amgen, Bank of America, Broadcom, CME, Goldman Sachs, Micron Technology, PepsiCo, UnitedHealth, Urban Outfitters and Vertex...
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of December.
Acadia shares made a handy gain on Monday after the firm announced positive results from an eight-week Phase 2 study evaluating pimavanserin as a therapy for Parkinson’s disease patients with...
The top analyst upgrades, downgrades and initiations seen on Friday included Acadia Pharmaceuticals, Broadcom, CBOE Global Markets, Etsy, Gap, General Electric, Home Depot, Lowe's Companies, Oracle...
Acadia Pharmaceuticals shares rose sharply early Monday after the firm announced that its late-stage dementia study met its primary endpoint.
Acadia Pharmaceuticals shares dropped on Tuesday after the firm announced results from its late-stage study for the treatment of adult schizophrenia patients.
Acadia Pharmaceuticals shares dipped on Wednesday despite announcing positive top-line results from its Clarity mid-stage study in major depressive disorder (MDD).
Acadia Pharmaceuticals shares popped after the company announced that the FDA completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of Nuplazid...
The top analyst upgrades, downgrades and initiations seen on Friday include AMD, Alcoa, AT&T, Darden Restaurants, Micron Technology, New Age Beverages, Nike, Novavax, Pier 1 Imports and Under...
With 2018 coming to a close in just a few months, Merrill Lynch is taking a close look at the biotech industry and what key catalysts to expect before 2019.
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
Ultra Petroleum, Coty, e.l.f. Beauty, and Acadia Pharmaceuticals all posted new 52-week lows Thursday.